vs
Side-by-side financial comparison of BCB BANCORP INC (BCBP) and ARS Pharmaceuticals, Inc. (SPRY). Click either name above to swap in a different company.
ARS Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($28.1M vs $26.2M, roughly 1.1× BCB BANCORP INC). BCB BANCORP INC runs the higher net margin — -49.7% vs -147.1%, a 97.5% gap on every dollar of revenue. On growth, BCB BANCORP INC posted the faster year-over-year revenue change (13.1% vs -67.6%).
ARS Pharmaceuticals, Inc. is a late-stage biopharmaceutical firm specializing in the development and commercialization of novel therapies for severe allergic reactions, most notably needle-free epinephrine delivery solutions for anaphylaxis. It primarily operates in the North American market, catering to both pediatric and adult patient groups at risk of life-threatening allergic responses.
BCBP vs SPRY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $26.2M | $28.1M |
| Net Profit | $-12.0M | $-41.3M |
| Gross Margin | — | — |
| Operating Margin | -71.9% | -147.6% |
| Net Margin | -49.7% | -147.1% |
| Revenue YoY | 13.1% | -67.6% |
| Net Profit YoY | -467.6% | -182.8% |
| EPS (diluted) | $-0.73 | $-0.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $26.2M | $28.1M | ||
| Q3 25 | $26.5M | $32.5M | ||
| Q2 25 | $25.2M | $15.7M | ||
| Q1 25 | $23.8M | $8.0M | ||
| Q4 24 | $23.1M | $86.6M | ||
| Q3 24 | $26.2M | $2.1M | ||
| Q2 24 | $20.4M | $500.0K | ||
| Q1 24 | $25.3M | $0 |
| Q4 25 | $-12.0M | $-41.3M | ||
| Q3 25 | $4.3M | $-51.2M | ||
| Q2 25 | $3.6M | $-44.9M | ||
| Q1 25 | $-8.3M | $-33.9M | ||
| Q4 24 | $3.3M | $49.9M | ||
| Q3 24 | $6.7M | $-19.1M | ||
| Q2 24 | $2.8M | $-12.5M | ||
| Q1 24 | $5.9M | $-10.3M |
| Q4 25 | -71.9% | -147.6% | ||
| Q3 25 | 21.9% | -163.7% | ||
| Q2 25 | 19.9% | -302.9% | ||
| Q1 25 | -49.2% | -466.3% | ||
| Q4 24 | 19.9% | 54.5% | ||
| Q3 24 | 35.7% | -1051.6% | ||
| Q2 24 | 19.5% | -3068.0% | ||
| Q1 24 | 33.0% | — |
| Q4 25 | -49.7% | -147.1% | ||
| Q3 25 | 16.1% | -157.4% | ||
| Q2 25 | 14.2% | -285.6% | ||
| Q1 25 | -35.0% | -425.7% | ||
| Q4 24 | 14.1% | 57.7% | ||
| Q3 24 | 25.5% | -925.0% | ||
| Q2 24 | 13.8% | -2503.2% | ||
| Q1 24 | 23.2% | — |
| Q4 25 | $-0.73 | $-0.41 | ||
| Q3 25 | $0.22 | $-0.52 | ||
| Q2 25 | $0.18 | $-0.46 | ||
| Q1 25 | $-0.51 | $-0.35 | ||
| Q4 24 | $0.17 | $0.52 | ||
| Q3 24 | $0.36 | $-0.20 | ||
| Q2 24 | $0.14 | $-0.13 | ||
| Q1 24 | $0.32 | $-0.11 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $245.0M |
| Total DebtLower is stronger | — | $96.4M |
| Stockholders' EquityBook value | $304.3M | $114.3M |
| Total Assets | $3.3B | $327.7M |
| Debt / EquityLower = less leverage | — | 0.84× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $245.0M | ||
| Q3 25 | — | $288.2M | ||
| Q2 25 | — | $240.1M | ||
| Q1 25 | — | $275.7M | ||
| Q4 24 | — | $314.0M | ||
| Q3 24 | — | $204.6M | ||
| Q2 24 | — | $218.7M | ||
| Q1 24 | — | $223.6M |
| Q4 25 | — | $96.4M | ||
| Q3 25 | — | $96.2M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $304.3M | $114.3M | ||
| Q3 25 | $318.5M | $147.7M | ||
| Q2 25 | $315.7M | $192.3M | ||
| Q1 25 | $314.7M | $229.0M | ||
| Q4 24 | $323.9M | $256.8M | ||
| Q3 24 | $328.1M | $201.0M | ||
| Q2 24 | $320.7M | $215.2M | ||
| Q1 24 | $320.1M | $223.9M |
| Q4 25 | $3.3B | $327.7M | ||
| Q3 25 | $3.4B | $372.8M | ||
| Q2 25 | $3.4B | $313.5M | ||
| Q1 25 | $3.5B | $327.3M | ||
| Q4 24 | $3.6B | $351.2M | ||
| Q3 24 | $3.6B | $217.6M | ||
| Q2 24 | $3.8B | $222.0M | ||
| Q1 24 | $3.8B | $227.6M |
| Q4 25 | — | 0.84× | ||
| Q3 25 | — | 0.65× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.9M | $-43.5M |
| Free Cash FlowOCF − Capex | $34.9M | — |
| FCF MarginFCF / Revenue | 133.3% | — |
| Capex IntensityCapex / Revenue | 4.0% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $58.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.9M | $-43.5M | ||
| Q3 25 | $8.7M | $-47.0M | ||
| Q2 25 | $10.3M | $-39.6M | ||
| Q1 25 | $5.0M | $-40.7M | ||
| Q4 24 | $67.7M | $42.0M | ||
| Q3 24 | $43.5M | $-14.5M | ||
| Q2 24 | $8.1M | $-7.3M | ||
| Q1 24 | $8.3M | $-6.7M |
| Q4 25 | $34.9M | — | ||
| Q3 25 | $8.5M | $-47.2M | ||
| Q2 25 | $10.2M | $-39.6M | ||
| Q1 25 | $4.7M | $-40.8M | ||
| Q4 24 | $66.5M | $41.7M | ||
| Q3 24 | $43.4M | $-14.6M | ||
| Q2 24 | $8.1M | $-7.3M | ||
| Q1 24 | $8.1M | $-6.8M |
| Q4 25 | 133.3% | — | ||
| Q3 25 | 32.0% | -145.4% | ||
| Q2 25 | 40.4% | -252.2% | ||
| Q1 25 | 19.8% | -512.1% | ||
| Q4 24 | 287.5% | 48.2% | ||
| Q3 24 | 166.0% | -706.3% | ||
| Q2 24 | 39.6% | -1463.4% | ||
| Q1 24 | 32.3% | — |
| Q4 25 | 4.0% | 0.0% | ||
| Q3 25 | 1.1% | 0.6% | ||
| Q2 25 | 0.6% | 0.3% | ||
| Q1 25 | 1.2% | 1.1% | ||
| Q4 24 | 5.3% | 0.3% | ||
| Q3 24 | 0.3% | 6.8% | ||
| Q2 24 | 0.2% | 7.6% | ||
| Q1 24 | 0.6% | — |
| Q4 25 | — | — | ||
| Q3 25 | 2.05× | — | ||
| Q2 25 | 2.90× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 20.70× | 0.84× | ||
| Q3 24 | 6.53× | — | ||
| Q2 24 | 2.88× | — | ||
| Q1 24 | 1.41× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BCBP
Segment breakdown not available.
SPRY
| Products | $20.3M | 72% |
| Other | $7.8M | 28% |
